Condition
Persistent Idiopathic Facial Pain
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Withdrawn1
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06496841Completed
Transnasal Versus Suprazygomatic SPG Block in Persistant Idiopathic Facial Pain
NCT04775758Not ApplicableUnknownPrimary
Atypical Orofacial Pain Diagnostics and Differentiation.
NCT01920087Phase 2Withdrawn
Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain
Showing all 3 trials